MS Spasticity and Cannabis: Recent Research
For individuals living with Multiple Sclerosis (MS), managing the various physical and neurological symptoms that arise can be a complex journey. Many patients explore complementary options to help maintain their quality of life. To provide the most accurate information, we have gathered a roundup of recent research sourced from PubMed, the database maintained by the U.S. National Library of Medicine, which houses peer-reviewed scientific studies.
Please note: This article is for general educational purposes only and is not medical advice. The science surrounding cannabinoids is still evolving. You should always talk to your physician before starting any new treatment or changing your current medication regimen.
Cannabis and MS Symptom Management
Research continues to examine how specific cannabis extracts may interact with the nervous system to help manage the challenges associated with MS. One of the most discussed areas of study is spasticity—the stiffness and involuntary muscle spasms common in MS patients.
The Role of Nabiximols
A systematic review and meta-analysis published in Medical Sciences (Basel, Switzerland) looked at the use of nabiximols, which is a standardized extract of Cannabis sativa. While nabiximols are already recognized as an add-on therapy for those dealing with moderate to severe MS-related spasticity, this specific study sought to determine if the extract could provide relief for other symptoms beyond muscle stiffness. The researchers aimed to see how this therapy might fit into broader treatment algorithms for adult patients.
CBD and Neurodegeneration
Beyond standardized extracts, researchers are looking at individual compounds. A study in the European Journal of Medicinal Chemistry examined Cannabidiol (CBD), a non-intoxicating component of the plant. The researchers observed that CBD engages a wide network of targets relevant to neurodegeneration, suggesting its potential as a candidate for neurotherapeutic development, though they noted that its biological activity is heavily influenced by how it is formulated and metabolized by the body.
Broader Perspectives on Complementary Care
Because MS affects multiple systems in the body, researchers are using "mapping" techniques to see where the current science stands and where more data is needed.
- Identifying Gaps: A scoping review published in Multiple Sclerosis and Related Disorders created an evidence gap map to visually organize clinical research on complementary therapies for people with MS. This process helps clinicians see which interventions have been studied in randomized clinical trials and where more research is required.
- Pain Management: While not MS-specific, a critical perspective published in Farmacia Hospitalaria discussed the role of cannabis in treating chronic neuropathic pain. The authors suggested that cannabis may serve as a third-line option for difficult cases, observing that its primary benefit may be related to the emotional and affective experience of suffering rather than simply blocking pain signals.
Understanding the Limitations
It is important to remember that the scientific community views these findings as observations and suggestions rather than absolute certainties. For example, while certain compounds are being studied for their ability to inhibit glutamate release or target neurodegeneration, these are often exploratory trials or reviews of existing data.
Managing MS requires a personalized approach tailored to your specific medical history. If you are interested in whether medical cannabis is an appropriate addition to your care plan, we encourage you to talk to your physician. They can help you weigh the potential benefits against your current medications to ensure a safe and coordinated approach to your health.
Sources & references
These peer-reviewed studies are indexed on PubMed (U.S. National Library of Medicine); each links to its PubMed listing. Findings belong to the cited authors and journals.
- Tetrahydrocannabinol/cannabidiol in the treatment of restless legs syndrome. — Journal of neurology · PubMed
- Current role of cannabis in therapeutics: A critical perspective. — Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · PubMed
- Nabiximols in Multiple Sclerosis: Beyond Spasticity-An Exploratory Systematic Review and Meta-Analysis of Symptomatic Outcomes. — Medical sciences (Basel, Switzerland) · PubMed
- Phytocannabinoid cannabidiol (CBD) in neurodegenerative diseases: From polypharmacology to drug development. — European journal of medicinal chemistry · PubMed
- Complementary therapies for multiple sclerosis: Scoping review with evidence gap map. — Multiple sclerosis and related disorders · PubMed
- Management of Urinary Symptoms in Multiple Sclerosis: An Umbrella Review. — Neurourology and urodynamics · PubMed
Ready to get your Florida medical marijuana card?
Disabled veteran-owned · on-site physician · no hidden fees.